LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL

Authors :: Frédéric Pouliot
Jeffrey Y.C. Wong
Michael J. Morris
Kenneth L. Gage
Barry A. Siegel
Michael A. Gorin
Steven P. Rowe
Nancy Stambler
Janet Pollard
Steve Y. Cho
Lawrence Saperstein
Jessica Jensen
David Y. Josephson
Peter R. Carroll
Vivien Wong
Austin R. Pantel
Andrei Iagaru
Morand Piert
Source :: Journal of Urology. 203
Publication Year :: 2020
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2020.
Abstract: Introduction:Improved diagnostics are needed to better inform the treatment of men with biochemically recurrent (BCR) prostate cancer (PCa). 18F-DCFPyL is a novel PET agent that selectively binds w...

Subjects :: Oncology
18F-DCFPyL
medicine.medical_specialty
PET-CT
business.industry
Urology
breakpoint cluster region
Phases of clinical research
medicine.disease
Prostate cancer
Internal medicine
medicine
Recurrent prostate cancer
business

Full Text Access

Tools